0.8324

1.94% -0.0165

After Hours: .83 -0.0024 -0.29%

Bluejay Diagnostics Inc (BJDX)

Overview News Price History Financials Why BJDX Down? Discussions Forecast Stock Split

Bluejay Diagnostics Inc stock is traded at $0.8324, with a volume of 88,719. It is down -1.94% in the last 24 hours and down -16.76% over the past month. Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.

Previous Close:

$0.8489

Open:

$0.8403

24h Volume:

88,719

Relative Volume:

0.02

Market Cap:

$861.30K

Revenue:

Net Income/Loss:

$-6.90M

P/E Ratio:

-0.0594

EPS:

-14.0152

Net Cash Flow:

$-6.65M

1W Performance:

-7.51%

1M Performance:

-16.76%

6M Performance:

-57.31%

1Y Performance:

-85.24%

1-Day Range:

$0.8211

$0.8496

1-Week Range:

$0.818

$0.906

52-Week Range:

$0.818

$16.68

Bluejay Diagnostics Inc Stock (BJDX) Company Profile

Name

Bluejay Diagnostics Inc

Sector

Healthcare (1074)

Industry

Medical Devices (141)

Phone

(978) 631-0152

Address

360 MASSACHUSETTS AVENUE, SUITE 203, ACTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

BJDX's Discussions on Twitter

Compare BJDX vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BJDX Bluejay Diagnostics Inc	0.8324	971.91K	0	-6.90M	-6.65M	-14.02
ABT Abbott Laboratories	108.33	197.51B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	94.17	118.14B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	303.13	125.70B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	47.80	71.55B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	89.90	51.78B	6.30B	1.07B	1.09B	1.8406

Bluejay Diagnostics Inc Stock (BJDX) Latest News

Aug 31, 2026

NASDAQ Stocks Under $1: FNGR, DUO, EPOW, CYAB in Focus Now! - FinancialContent

Aug 31, 2026

Aug 28, 2026

BJDX Stock Draws Traders As Sepsis Test Milestones Hit - StocksToTrade

Aug 28, 2026

Aug 20, 2026

Armistice Capital Acquires 142,728 Shares of Bluejay Diagnostics Inc (BJDX) - GuruFocus

Aug 20, 2026

Aug 18, 2026

Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels: the Session Ends Within the Reported Technical Boundaries for the Current SessionGrowth ETF - vinanet.vn

Aug 18, 2026

Bluejay Diagnostics (BJDX) links director options to FDA nod - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (NASDAQ: BJDX) insider updates share holdings - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (NASDAQ: BJDX) ties director options to FDA clearance - Stock Titan

Aug 18, 2026

Aug 14, 2026

Armistice Capital discloses 9.99% Bluejay Diagnostics (BJDX) position in Schedule 13G - Stock Titan

Aug 14, 2026

Aug 13, 2026

Bluejay Diagnostics (BJDX) investor group discloses 9.99% ownership with warrants - Stock Titan

Aug 13, 2026

Form 8K Bluejay Diagnostics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Bluejay Advances Symphony Platform, Strengthens Cash Position - TipRanks

Aug 13, 2026

Form 8K Bluejay Diagnostics Inc For: 13 August - Investing.com India

Aug 13, 2026

Bluejay Diagnostics Q2 Results: EPS loss narrows 80% YoY to $(1.12) - scanx.trade

Aug 13, 2026

Bluejay Diagnostics completes enrollment in sepsis test study - Investing.com

Aug 13, 2026

Bluejay Diagnostics completes enrollment in sepsis test study By Investing.com - Investing.com Australia

Aug 13, 2026

Bluejay Diagnostics Completes Enrollment in SYMON-II Pivotal Study, Advances Toward 510(k) Submission and Commercialization - quiverquant.com

Aug 13, 2026

Bluejay completes 750-patient study enrollment for Symphony IL-6 - Stock Titan

Aug 13, 2026

Aug 12, 2026

Bluejay Diagnostics, Inc. Q2 2026: Net loss $(2.32M), EPS $(1.12) — 10-Q Summary - TradingView

Aug 12, 2026

Bluejay Diagnostics (BJDX) warns on going concern and Nasdaq listing risk - Stock Titan

Aug 12, 2026

Aug 07, 2026